Company intelligence / Profile preview
Fabre-Kramer Pharmaceuticals
Houston, Texas, United Statesfabrekramer.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Fabre-Kramer Pharmaceuticals received FDA approval for EXXUA (gepirone hydrochloride extended-release tablets) on September 29, 2023, for the treatment of Major Depressive Disorder in adults. The company has several other compounds in various stages of clinical development.
- Therapeutic areas
- Men's HealthPsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mission Pharmacal CompanyGlaxoSmithKline (GSK)
Beyond the preview
Go deeper on Fabre-Kramer Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fabre-Kramer Pharmaceuticals.